Seres Posts Flat Revenue Amid 8-Year Loss Streak and 38% Monthly Stock Drop

Seres Therapeutics (MCRB) reported fiscal 2025 Q4 earnings on March 12, 2026, with stable revenue of $438,000 and an EPS of -$1.70, consistent with the prior quarter. The company maintained its cash runway guidance through Q3 2026 but highlighted ongoing financial challenges despite clinical progress in key programs.

Revenue

The total revenue of Seres Therapeutics remained stable at $438,000 in 2025 Q4, with no significant change from the previous quarter.

Earnings/Net Income

Seres Therapeutics maintained stable EPS at $-1.70 in 2025 Q4 compared to the prior quarter. Meanwhile, the company’s net loss widened to $-15.34 million in 2025 Q4, representing a 0.0% increase from the $-15.34 million loss recorded in 2025 Q4. The Company has sustained losses for 8 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The company’s sustained losses and negative EPS underscore ongoing financial challenges despite clinical advancements.

Price Action

The stock price of Seres Therapeutics has edged up 0.56% during the latest trading day, has dropped 4.94% during the most recent full trading week, and has plummeted 38.14% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Seres Therapeutics (MCRB) shares after its revenue equalled quarter-over-quarter on the financial report released date and holding for 30 days resulted in a significant loss. The strategy had a CAGR of -47.10% and an excess return of -152.01%, with a maximum drawdown of 95.64% and a Sharpe ratio of -0.44. This indicates that the strategy was not only unsuccessful in generating returns but also posed a high risk to the investor's capital.

CEO Commentary

Richard Kender, Executive Chair and interim CEO, emphasized Seres’ focus on advancing live biotherapeutics for inflammatory and immune diseases, including SER-603 for IBD and SER-155 for immune checkpoint-related enterocolitis (irEC). He highlighted the Q2 2026 data readout for the SER-155 irEC trial, noting its potential to expand therapeutic opportunities, and reiterated Phase 2 readiness for SER-155 in allo-HSCT. Kender underscored prudent resource management, partnership pursuits, and collaboration discussions to fund pipeline development. The tone reflects cautious optimism, balancing clinical progress with financial constraints and the need for external funding.

Guidance

Seres expects to report SER-155 irEC trial data in Q2 2026 and advance SER-155 for allo-HSCT pending funding. The company anticipates cash runway through Q3 2026 based on $45.8 million in cash as of December 2025. Forward-looking statements include plans to secure partnerships or financing to extend operations, with no explicit revenue or EPS guidance provided. Risks include dependency on external funding, clinical trial outcomes, and regulatory uncertainties.

Additional News

Recent developments include a 25% workforce reduction to extend cash runway through Q2 2026, with R&D expenses cut to $12.6 million and G&A to $9.5 million. The company’s cash position stands at $45.8 million, with executives emphasizing SER-155’s “first-in-class, mechanistically differentiated approach.” Strategic focus has shifted to SER-155 for preventing bloodstream infections, with Phase 2 readiness contingent on securing additional funding. Management is exploring research partnerships in inflammatory and immune diseases, including potential applications in ulcerative colitis and Crohn’s disease.